Trinity Biotech Secures $7M from Perceptive, Regains Nasdaq Compliance
TRIB sits 52% above its 52-week low of $7.94 on light trading volume (0.2× avg).
Summary
Trinity Biotech secured $7 million in additional investment from Perceptive Advisors and regained Nasdaq compliance, strengthening its liquidity and removing a delisting risk.
Key Events · Financing and Capital Events · TRIB
-
Perceptive Provides $7M Investment
Perceptive Credit Holdings III, LP provided $2.5 million in new debt funding and capitalized $4.5 million of accrued interest under an amended credit agreement.
-
Nasdaq Compliance Regained
Trinity Biotech received confirmation on August 7, 2026, that it regained compliance with Nasdaq's minimum bid price requirement after 10 consecutive days above $1.00.
-
Liquidity Covenant Waived
The lender waived the minimum liquidity covenant for June, July, and August 2026, indicating the company was previously in breach.
-
Preliminary Q2 Revenue Flat
Preliminary Q2 2026 revenue was approximately $10.5 million, broadly consistent with Q1 2026.
Analysis · TRIB · Life Sciences
An amended credit agreement with Perceptive Credit Holdings III, LP delivers $2.5 million in new debt funding and capitalizes $4.5 million of accrued interest. The company also regained compliance with Nasdaq's minimum bid price requirement, removing a delisting overhang. The waiver of the minimum liquidity covenant for June through August 2026 indicates the company was in breach, but the lender's continued support and the new funding provide near-term liquidity. Preliminary Q2 revenue of $10.5 million is broadly flat versus Q1, suggesting stabilization.
At the time of this filing, TRIB was trading at $12.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.7M. The 52-week trading range was $7.94 to $103.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.